Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Leukemia ; 28(11): 2197-205, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24699302

RESUMEN

Acute myeloid leukemia (AML) primary cells express high levels of phosphorylated Akt, a master regulator of cellular functions regarded as a promising drug target. By means of reverse phase protein arrays, we examined the response of 80 samples of primary cells from AML patients to selective inhibitors of the phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) axis. We confirm that >60% of the samples analyzed are characterized by high pathway phosphorylation. Unexpectedly, however, we show here that targeting Akt and mTOR with the specific inhibitors Akti 1/2 and Torin1, alone or in combination, result in paradoxical Akt phosphorylation and activation of downstream signaling in 70% of the samples. Indeed, we demonstrate that cropping Akt or mTOR activity can stabilize the Akt/mTOR downstream effectors Forkhead box O and insulin receptor substrate-1, which in turn potentiate signaling through upregulation of the expression/phosphorylation of selected growth factor receptor tyrosine kinases (RTKs). Activation of RTKs in turn reactivates PI3K and downstream signaling, thus overruling the action of the drugs. We finally demonstrate that dual inhibition of Akt and RTKs displays strong synergistic cytotoxic effects in AML cells and downmodulates Akt signaling to a much greater extent than either drug alone, and should therefore be explored in AML clinical setting.


Asunto(s)
Leucemia Mieloide Aguda/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Serina-Treonina Quinasas TOR/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Benzotiazoles/farmacología , Sinergismo Farmacológico , Retroalimentación Fisiológica/efectos de los fármacos , Retroalimentación Fisiológica/fisiología , Humanos , Indoles/farmacología , Leucemia Mieloide Aguda/tratamiento farmacológico , Persona de Mediana Edad , Compuestos de Fenilurea/farmacología , Fosforilación/efectos de los fármacos , Fosforilación/fisiología , Proteoma/antagonistas & inhibidores , Proteoma/metabolismo , Pirroles/farmacología , Estudios Retrospectivos , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Sunitinib , Células Tumorales Cultivadas , Adulto Joven
2.
Mol Hum Reprod ; 15(8): 499-506, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19542546

RESUMEN

High activity of the phosphoinositide 3-kinase/Akt pathway in cumulus cells plays an important role in FSH regulation of cell function and Protein Kinase C epsilon (PKCepsilon) collaborates with these signalling pathways to regulate cell proliferation. Relevant roles in follicular development are played by Maternal Antigen That Embryos Require (MATER) that is a cumulus cell- and oocyte-specific protein dependent on the maternal genome. We recently demonstrated that human MATER localizes at specific domains of oocytes and, for the first time, also in cumulus cells. MATER contains a carboxy-terminal leucine-rich repeat domain involved in protein-protein interactions regulating different cellular functions. Here we investigated the functional role of MATER. Thus, we performed coimmunoprecipitation experiments using HEK293T cells expressing human MATER; a similar approach was then followed in human cumulus/follicular cells. In MATER(+)HEK293T cells, we observed that this protein acts as a phosphorylation substrate of PKCepsilon. Western blot experiments indicate that, unlike oocytes, human cumulus cells express PKCepsilon. Immunoprecipitation and confocal analysis suggest for the first time that MATER protein interacts with this protein kinase in cumulus cells under physiological conditions. Since PKCepsilon is known to collaborate with antiapoptotic signalling pathways, this suggests a novel mechanism for the function of MATER in follicular maturation.


Asunto(s)
Autoantígenos/metabolismo , Células del Cúmulo/metabolismo , Proteína Quinasa C-epsilon/metabolismo , Autoantígenos/genética , Línea Celular , Células Cultivadas , Electroforesis , Humanos , Inmunoprecipitación , Microscopía Confocal , Microscopía Fluorescente , Proteínas Mitocondriales , Proteínas Nucleares , Fosforilación , Unión Proteica
3.
Oncogene ; 26(48): 6915-26, 2007 Oct 18.
Artículo en Inglés | MEDLINE | ID: mdl-17486073

RESUMEN

Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation. We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analysing its level in two variants of CEM cells, namely S-CEM and R-CEM, normally sensitive or resistant to chemical apoptosis, respectively. We found that, while the CK2 regulatory subunit beta was equally expressed in the two cell variants, CK2alpha catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates. Pharmacological downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2alpha expression by RNA interference, were able to induce cell death in R-CEM. CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner. CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS). We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.


Asunto(s)
Quinasa de la Caseína II/antagonistas & inhibidores , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Linfocitos T/patología , Animales , Antibióticos Antineoplásicos/metabolismo , Antineoplásicos Fitogénicos/farmacología , Apoptosis/fisiología , Western Blotting , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/patología , Quinasa de la Caseína II/genética , Quinasa de la Caseína II/metabolismo , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Doxorrubicina/metabolismo , Humanos , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/patología , Fosforilación , ARN Interferente Pequeño/farmacología , Conejos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Linfocitos T/efectos de los fármacos , Transfección , Vinblastina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA